{
 "awd_id": "8620033",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "Biological Production of Perdeuterated Oils for Lubricant   Synthesis",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Ritchie B. Coryell",
 "awd_eff_date": "1987-12-15",
 "awd_exp_date": "1989-11-30",
 "tot_intn_awd_amt": 202123.0,
 "awd_amount": 202123.0,
 "awd_min_amd_letter_date": "1988-02-05",
 "awd_max_amd_letter_date": "1988-02-05",
 "awd_abstract_narration": "This work is directed at reducing the cost of biological                   production of perdeuterated chemical feedstock to increase the                  availability of deuterated lubricants (hydrogen is replaced by                  deuterium) for commercial use.  Preliminary studies have                        confirmed the technological feasibility of using a                              biotechnological strategy that involves the growth of oil                       producing algae in deuterium oxide (heavy water), thereby,                      utilizing the biochemical pathways of the organism to                           synthesize the perdeuterated oils.  Perdeuterated lubricants                    exhibit an increased stability over the equivalent hydrocarbons                 under high temperature and oxidizing conditions due to the                      increased carbon-deuterium bond strength.  This results in a                    five to ten fold increase in performance lifetime.                                   Upon completion of Phase II (yield improvement), it is                     hoped to have a photobioreactor operating continuously with                     minimal D20 losses, and production data which will allow                        assessment of the commercial potential of the biodeuteration                    approach.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "David",
   "pi_last_name": "Kyle",
   "pi_mid_init": "J",
   "pi_sufx_name": "",
   "pi_full_name": "David J Kyle",
   "pi_email_addr": "DKyle@ABN-Corp.com",
   "nsf_id": "000055002",
   "pi_start_date": "1987-12-15",
   "pi_end_date": null
  },
  {
   "pi_role": "Co-Principal Investigator",
   "pi_first_name": "Paul",
   "pi_last_name": "Behrens",
   "pi_mid_init": "",
   "pi_sufx_name": "",
   "pi_full_name": "Paul Behrens",
   "pi_email_addr": "",
   "nsf_id": "000228910",
   "pi_start_date": "1987-12-15",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Martek Biosciences Corporation",
  "inst_street_address": "6480 Dobbin Road",
  "inst_street_address_2": "",
  "inst_city_name": "Columbia",
  "inst_state_code": "MD",
  "inst_state_name": "Maryland",
  "inst_phone_num": "4107400081",
  "inst_zip_code": "210455825",
  "inst_country_name": "United States",
  "cong_dist_code": "03",
  "st_cong_dist_code": "MD03",
  "org_lgl_bus_name": null,
  "org_prnt_uei_num": null,
  "org_uei_num": null
 },
 "perf_inst": {
  "perf_inst_name": "DATA NOT AVAILABLE",
  "perf_str_addr": "",
  "perf_city_name": "",
  "perf_st_code": "",
  "perf_st_name": "RI REQUIRED",
  "perf_zip_code": "",
  "perf_ctry_code": "",
  "perf_cong_dist": "",
  "perf_st_cong_dist": "",
  "perf_ctry_name": "",
  "perf_ctry_flag": "0"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537300",
   "pgm_ele_name": "SBIR Phase II"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1402",
   "pgm_ref_txt": "BIOCHEMICAL & BIOMASS ENG"
  },
  {
   "pgm_ref_code": "5373",
   "pgm_ref_txt": "SMALL BUSINESS PHASE II"
  }
 ],
 "app_fund": [
  {
   "app_code": "",
   "app_name": "",
   "app_symb_id": "",
   "fund_code": "",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 1988,
   "fund_oblg_amt": 202123.0
  }
 ],
 "por": null
}